Japan electroceuticals market is expected to grow at a CAGR of 7.1% during the forecast period. Geriatric population is one of the major concerns for the Japanese government and other healthcare institution. According to US Census Bureau, out of total 126 million population, about 27% population of the country was above 65 years in 2017. It is forecast that the population will reduce to 123 million in 2023 and geriatric population is forecast to be higher as compared to 2017. Additionally, life expectancy of the people in Japan is the highest globally. The incidence of heart stroke occurrence in geriatric population is relatively high as compared to young population. As per the Institute for Health Metrics and Evaluation, in 2017, around 0.2 million incidences of ischemic heart disease occurred in Japan. The prevalence of Ischemic heart disease in 2013 was 3.5 million peoples that have increased to 3.7 million in 2017.
To Request a Sample of our Report on Japan Electroceuticals Market: https://www.omrglobal.com/request-sample/japan-electroceuticals-market
The other major factor that provides significant growth to the market is product approval in the country. LivaNova had received Japan’s Ministry of Health, Labour & Welfare approval for Perceval suture less aortic heart valve to treat aortic valve disease that enables to provide patients and clinicians in Japan with a new option for aortic heart valve replacement. Additionally, the company had received the US FDA 510(k) clearance of the MEMO4D semi-rigid mitral annuloplasty ring and confirmed the first implantation of the device.
(Get 15% Discount on Buying this Report)
A full Report of Japan Electroceuticals Market is Available at: https://www.omrglobal.com/industry-reports/japan-electroceuticals-market
Japan Electroceuticals Market Segmentation
By Product and its Application
· Cardioverter Defibrillators and Cardiac Pacemaker
· Arrhythmias
· Deep Brain Stimulators
· Parkinson’s Disease
· Depression
· Spinal Cord Stimulators
· Failed Back Syndrome
· Ischemia
· Vagus Nerve Stimulators
· Epilepsy
· Cochlear Implants
· Sensorineural Hearing Loss
· Others (Sacral Nerve Stimulators, Transcutaneous Electrical Nerve Stimulators)
· Urinary Incontinence
· Treatment-Resistant Depression
By End-User
· Hospitals and Clinics
· Homecare and Other
(This release has been published on OMR Industry Journal. OMR Industry Journal is not responsible for any content included in this release.)
